Hims & Hers Health Faces Class Action Lawsuit Following FTC Allegations, Stock Plummets

Hims & Hers Health Faces Class Action Lawsuit

Hims & Hers Health, Inc. (NYSE: HIMS) is currently embroiled in a major legal battle as it faces a securities class action lawsuit following serious allegations from the Federal Trade Commission (FTC). The lawsuit, spearheaded by Hagens Berman Sobol Shapiro LLP, is a result of accusations that the company engaged in significant misconduct, particularly regarding the handling of consumer health information.

Background of the Case

The FTC has raised concerns regarding the business practices of Hims & Hers, specifically pointing to violations that could have grave implications. The foundation of the case draws from a federal complaint issued by the FTC on July 29, 2026, which highlights multiple allegations. These include improper sharing of sensitive health data with advertising firms and hindering consumers from easily canceling subscription services.

Allegations of Misconduct

According to the lawsuit, Hims & Hers has been accused of:
1. Deceptive Data Practices: Despite public commitments to privacy, the FTC alleges that the company shared confidential consumer health information with third-party advertising services like Meta Platforms (Facebook) and Snap through tracking technology.
2. Subscription Billing Issues: The lawsuit further asserts that consumers were enrolled into recurring payment models without proper consent. Customers were charged for prescriptions immediately after completing intake forms, without the opportunity for a proper consultation with a healthcare professional. This practice is seen as a violation of the Restore Online Shoppers' Confidence Act (ROSCA), which mandates transparency and consent in such transactions.

Market Impact

The fallout from these allegations has been substantial. Following the announcement of the FTC's complaint, Hims & Hers's stock plummeted by 14.7%, resulting in a staggering market value loss exceeding $970 million in just one trading day. Investors are left scrambling to determine the ramifications of this legal action and its potential impact on the company's future.

The Call for Investor Action

Hagens Berman, representing the lead plaintiffs, is actively seeking investors who have experienced significant losses due to these developments. The law firm is emphasizing the importance of acting quickly, as potential lead plaintiff deadlines approach on November 2, 2026. Investors with insights or knowledge relevant to the investigation are urged to participate and share information that may prove critical to the lawsuit.

Looking Forward

The outcome of this case could set a precedent for regulatory actions against companies in the telehealth sector, where consumer data privacy is paramount. Legal experts are closely monitoring this situation, as it may influence corporate governance and operational transparency in the industry moving forward. Hims & Hers Health's CEO and other executives are expected to be scrutinized to determine if they intentionally misled investors regarding the company's practices and the adequacy of its internal controls.

In conclusion, the situation surrounding Hims & Hers underscores the growing scrutiny that companies in the health tech sector face regarding privacy and ethical marketing practices. As the legal proceedings unfold, all eyes will be on how Hims & Hers manages its defense and navigates the complexities of regulatory compliance in this rapidly evolving marketplace.

For those affected by this situation, or for individuals with additional information, now is the time to act. The unfolding of events will be pivotal in shaping the future landscape of telehealth services and investor trust in the sector.